Oxford Biomedica reiterates full-year guidance, flags first-half loss
26th Mar 2026 10:30
(Sharecast News) - Oxford Biomedica posted a surge in annual revenues on Thursday, but warned it was on track to swing to an interim loss this year before returning to growth in the second half.
Read moreEQT not planning to bid for Oxford Biomedica
25th Feb 2026 12:36
(Sharecast News) - Oxford Biomedica shares slumped on Wednesday after Swedish private equity firm EQT said it was not planning to make an offer for the gene and cell therapy company.
Read moreOxford Biomedica FY revenues grow, one‑off gain props up earnings
24th Feb 2026 07:36
(Sharecast News) - Contract development and manufacturing firm Oxford Biomedica said on Tuesday that it expects to report a strong rise in full year revenues, but signalled that underlying profitability would only be modest despite a one‑off boost from its US acquisition.
Read moreOxford Biomedica extends 'put up or shut up' deadline as EQT talks continue
11th Feb 2026 15:07
(Sharecast News) - Oxford Biomedica said on Wednesday that the deadline for EQT to make a formal takeover bid has been extended amid ongoing preliminary discussions.
Read moreOxford Biomedica signs expanded CAR‑T supply pact with Bristol Myers Squibb
4th Feb 2026 07:56
(Sharecast News) - Gene and cell therapy company Oxford Biomedica said on Wednesday that it has expanded its strategic partnership with Bristol Myers Squibb, inking a new commercial supply agreement for the manufacture and supply of lentiviral vectors for BMS' CAR-T programmes.
Read moreOxford Biomedica confirms takeover approach from PE firm EQT
14th Jan 2026 16:57
(Sharecast News) - Oxford Biomedica confirmed on Wednesday that it has received unsolicited takeover approaches from private equity firm EQT.
Read moreOxford Biomedica acquires US viral vector facility
7th Oct 2025 09:12
(Sharecast News) - Cell and gene therapy outfit Oxford Biomedica said on Tuesday that it had agreed to acquire a viral vector manufacturing site in Rockville, Maryland, from ABL for $60m in cash, expanding its US footprint and strengthening its contract development and manufacturing offering.
Read moreOxford Biomedica reiterates outlook as interim losses narrow
23rd Sep 2025 08:29
(Sharecast News) - Oxford Biomedica reiterated full-year guidance on Tuesday, after the biopharma saw strong demand throughout the first half and trimmed losses.
Read moreRBC Capital Markets raises target price on OXB
26th Aug 2025 08:41
(Sharecast News) - Analysts at RBC Capital Markets hiked their target price on gene and cell therapy firm OXB from 800p to 930p on Tuesday following its recent oversubscribed £60m equity funding and revenue guidance reiteration.
Read moreOxford Biomedica raises £60m to bolster US capacity
15th Aug 2025 07:36
(Sharecast News) - Oxford Biomedica has raised £60m via a share placing and subcription to expand its US operations, the gene and cell therapy company announced on Friday.
Read moreOxford Biomedica agrees new four-year, $125m loan facility
1st Aug 2025 10:52
(Sharecast News) - Oxford Biomedica announced on Friday that it has agreed a new four-year loan facility of up to $125m with Oaktree Capital Management, refinancing its existing debt and providing additional funding capacity to support future expansion.
Read moreOxford Biomedica flags sharp rise in first-half revenue
28th Jul 2025 11:41
(Sharecast News) - Oxford Biomedica reported a sharp rise in first-half revenue and strong commercial momentum on Monday, as it reiterated its full-year guidance and pointed to growing demand across its cell and gene therapy manufacturing platforms.
Read moreOxford Biomedica acquires last 10pc stake in US subsidiary
23rd Jun 2025 11:20
(Sharecast News) - Oxford Biomedica said on Monday it has acquired the remaining 10% stake in its US subsidiary, OXB US, from Q32 Bio, bringing its ownership of the business to 100% as previously planned.
Read moreOxford Biomedica reports first-half revenue growth
23rd Sep 2024 11:16
(Sharecast News) - Oxford Biomedica, a prominent gene and cell therapy company, reported significant revenue growth alongside strategic advancements in its interim results on Monday.
Read moreOxford Biomedica still expecting small loss after solid first half
8th Aug 2024 12:38
(Sharecast News) - Cell and gene therapy contract development and manufacturing organisation Oxford Biomedica reported a strong first-half trading performance in an update on Thursday, with revenue expected to reach £50m.
Read more